DOES THE USE OF ERYTHROPOIETIN IN HEMODIALYSIS-PATIENTS INCREASE DIALYSIS GRAFT THROMBOSIS RATES

被引：12

作者：

STANDAGE, BA ^{[1
]}

SCHUMAN, ES ^{[1
]}

ACKERMAN, D ^{[1
]}

GROSS, GF ^{[1
]}

RAGSDALE, JW ^{[1
]}

机构：

[1] GOOD SAMARITAN HOSP, DEPT SURG, PORTLAND, OR 97210 USA

来源：

AMERICAN JOURNAL OF SURGERY | 1993年 / 165卷 / 05期

关键词：

D O I：

10.1016/S0002-9610(05)80454-4

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Erythropoietin (EPO) is highly efficacious in the treatment of the anemia of chronic renal failure. Evidence for a reported serious side effect, increased dialysis graft thrombosis, is equivocal. Sixty-four hemodialysis patients utilizing polytetrafluoroethylene (PTFE) grafts were treated with EPO. The patients served as their own historical controls. There were 1.188 thrombectomies and 0.222 mechanical problems per 1,000 patient-days prior to the initiation of EPO treatment. With EPO, the values were 0.656 and 0.222, respectively. Patients were separated into low-, medium-, and high-dose EPO groups and analyzed within groups for the effect of EPO and between groups for a dose-dependent response. According to an analysis of variance procedure, there was no statistically significant differences between the groups, which suggests that EPO is not thrombogenic to dialysis grafts.

引用

页码：650 / 654

页数：5

共 26 条

[1]

Besarab A, 1990, ASAIO Trans, V36, pM749

[2]

Bommer J, 1988, Contrib Nephrol, V66, P85

[3] BENEFITS AND RISKS OF PROTRACTED TREATMENT WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS HAVING HEMODIALYSIS [J].

CASATI, S ;

PASSERINI, P ;

CAMPISE, MR ;

GRAZIANI, G ;

CESANA, B ;

PERISIC, M ;

PONTICELLI, C .

BMJ-BRITISH MEDICAL JOURNAL, 1987, 295 (6605) :1017-1020

[4]

DY ER, 1991, ASAIO T, V37, pM274

[5] TREATMENT OF THE ANEMIA OF PROGRESSIVE RENAL-FAILURE WITH RECOMBINANT HUMAN ERYTHROPOIETIN [J].

ESCHBACH, JW ;

KELLY, MR ;

HALEY, NR ;

ABELS, RI ;

ADAMSON, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) :158-163

[6] RECOMBINANT HUMAN ERYTHROPOIETIN IN ANEMIC PATIENTS WITH END-STAGE RENAL-DISEASE - RESULTS OF A PHASE-III MULTICENTER CLINICAL-TRIAL [J].

ESCHBACH, JW ;

ABDULHADI, MH ;

BROWNE, JK ;

DELANO, BG ;

DOWNING, MR ;

EGRIE, JC ;

EVANS, RW ;

FRIEDMAN, EA ;

GRABER, SE ;

HALEY, NR ;

KORBET, S ;

KRANTZ, SB ;

LUNDIN, AP ;

NISSENSON, AR ;

OGDEN, DA ;

PAGANINI, EP ;

RADER, B ;

RUTSKY, EA ;

STIVELMAN, J ;

STONE, WJ ;

TESCHAN, P ;

VANSTONE, JC ;

VANWYCK, DB ;

ZUCKERMAN, K ;

ADAMSON, JW .

ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) :992-1000

[7]

GROSS GF, 1979, AM SURGEON, V45, P748

[8]

GRUTZMACHER P, 1989, NEPHROL DIAL TRANSPL, V4, P473

[9] CHANGES IN DETERMINANTS OF BLOOD RHEOLOGY DURING TREATMENT WITH HEMODIALYSIS AND RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].

KOPPENSTEINER, R ;

STOCKENHUBER, F ;

JAHN, C ;

BALCKE, P ;

MINAR, E ;

EHRINGER, H .

BMJ-BRITISH MEDICAL JOURNAL, 1990, 300 (6740) :1626-1627

[10]

LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573

← 1 2 3 →